Targeting LOXL2 and cardiac fibrosis to improve heart failure treatment
Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart Failure Treatment- A Prospective Study
This study is testing if a new rehabilitation program can help heart failure patients feel better and live longer by looking at a specific protein and other health factors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 20 Years to 100 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Trial ID | NCT05498584 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of lysyl oxidase-like 2 (LOXL2) in cardiac fibrosis among patients with heart failure. It aims to assess the effectiveness of a multidisciplinary cardiac rehabilitation program in reducing mortality and improving outcomes for patients discharged from acute heart failure. The study will analyze predictors of successful rehabilitation, including LOXL2 levels, cardiac MRI results, and endothelial function. By focusing on these factors, the researchers hope to enhance the quality of care and reduce readmission rates for heart failure patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 20 and older with heart failure classified as NYHA class II-IV and specific BNP or NT-proBNP levels.
Not a fit: Patients with an estimated survival time of less than 6 months or those who are ventilator dependent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates and quality of life for patients with heart failure.
How similar studies have performed: Previous studies have shown promising results in cardiac rehabilitation programs for heart failure, suggesting that this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients must give written informed consent before any assessment is performed. 2. Inpatients \>= 20 years of age, male or female. 3. Patients with a diagnosis of heart failure New York Heart Association (NYHA) class II-IV with BNP \>=100 pg/mL or NT-porBNP \>= 400 pg/mL ( \>= 900 pg/mL if concomitant atrial fibrillation) 4. Left ventricular ejection fraction \<= 40% by echocardiography or other methods Exclusion Criteria: 1. Estimated survival time \< 6 months 2. Long-term bedridden for more than 3 months 3. Cannot tolerate exercise test due to muscular skeletal disorder. 4. Cannot cooperate all functional studies 5. Ventilator dependent 6. Terminal heart status 7. Family rejects to participate in this project 8. Primary severe valvular heart disease
Where this trial is running
Kaohsiung City
- Chang Gung Memorial Hospital Heart Failure Center — Kaohsiung City, Taiwan (Recruiting)
Study contacts
- Principal investigator: Shyh-Ming Che, MD — Chang Gung Medical Foundation
- Study coordinator: Hsin-Yen Tsai
- Email: milktea588@gmail.com
- Phone: +886929610850
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.